TLX3 and acute lymphoblastic leukemia: We preliminarily screened 26 patients with T-ALL for diagnostic molecular characterization and we found 5 cases with PTEN-Exon7 mutation (19%), 3 with PICALM/MLLT10 rearrangement (11.5%), 7 with TLX3 (HOX11L2) alteration (27%), 1 with mutated TP53 (4%), 16 with CDKN2A deletion (61.5%) and 6 with CRLF2 overexpression (23%); additionally, 3 out of 20 patients exhibited IKZF1 deletion (15%), respectively (Supplementary Table S1).